CST3 and chronic kidney disease: CKD patients in the CKDu-affected area were characterized by high urinary Cystatin-C, low urinary DMAP detection and higher urinary concentration of dinotefuran and imidacloprid, and seven symptoms (finger tremor, fever, high volume urine, appetite loss, reduced body weight, abnormal behavior and constipation).